Hepatitis C virus infection in the elderly: Epidemiology, natural history and management

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection frequently occurs in elderly individuals, with a prevalence in individuals aged >60 years of up to approximately 40%. Although progression to cirrhosis is accelerated and occurs more frequently in patients who acquire the infection in old age, this outcome is often not seen because most elderly infected patients acquired HCV when they were young. Data on progression of HCV infection to cirrhosis and eventually to hepatocellular carcinoma are often derived from studies of HCV-infected individuals who present or are referred to hospitals, and which are therefore likely to overestimate the seriousness of the disease; indeed, population-based studies indicate that in many elderly individuals the disease is asymptomatic and runs a fairly benign course. Treatment is based on use of pegylated interferon-α and ribavirin, and is overall less effective and more toxic in the elderly. Therefore, treatment should be carefully considered on an individual basis and proposed only in patients up to the age of 75 years with a significant risk of progression of liver disease, no serious co-morbidities and good life expectancy. All treated patients should be followed long term in order to assess the influence of therapy on the evolution of liver disease (decompensated cirrhosis, hepatocellular carcinoma) and survival. It is hoped that liver biopsy, which is still required in order to assess prognosis appropriately, will be replaced in the future by less invasive methods based on combinations of biochemical markers of fibrosis and/or transient elastography, and that newer and less toxic orally administered drugs for HCV infection will become available.

Original languageEnglish
Pages (from-to)9-18
Number of pages10
JournalDrugs and Aging
Volume25
Issue number1
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Virus Diseases
Natural History
Hepacivirus
Epidemiology
Fibrosis
Poisons
Liver Diseases
Hepatocellular Carcinoma
Elasticity Imaging Techniques
Asymptomatic Diseases
Ribavirin
Life Expectancy
Interferons
Therapeutics
Biomarkers
Morbidity
Biopsy
Survival
Liver
Infection

Keywords

  • Elderly
  • Hepatitis C, treatment
  • Peginterferon alfa 2b/ribavirin, therapeutic use
  • Peginterferon alfa, therapeutic use
  • Ribavirin, therapeutic use

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology

Cite this

Hepatitis C virus infection in the elderly : Epidemiology, natural history and management. / Cainelli, Francesca.

In: Drugs and Aging, Vol. 25, No. 1, 2008, p. 9-18.

Research output: Contribution to journalReview article

@article{a49f9805253c4f92b53ea4ca93640809,
title = "Hepatitis C virus infection in the elderly: Epidemiology, natural history and management",
abstract = "Hepatitis C virus (HCV) infection frequently occurs in elderly individuals, with a prevalence in individuals aged >60 years of up to approximately 40{\%}. Although progression to cirrhosis is accelerated and occurs more frequently in patients who acquire the infection in old age, this outcome is often not seen because most elderly infected patients acquired HCV when they were young. Data on progression of HCV infection to cirrhosis and eventually to hepatocellular carcinoma are often derived from studies of HCV-infected individuals who present or are referred to hospitals, and which are therefore likely to overestimate the seriousness of the disease; indeed, population-based studies indicate that in many elderly individuals the disease is asymptomatic and runs a fairly benign course. Treatment is based on use of pegylated interferon-α and ribavirin, and is overall less effective and more toxic in the elderly. Therefore, treatment should be carefully considered on an individual basis and proposed only in patients up to the age of 75 years with a significant risk of progression of liver disease, no serious co-morbidities and good life expectancy. All treated patients should be followed long term in order to assess the influence of therapy on the evolution of liver disease (decompensated cirrhosis, hepatocellular carcinoma) and survival. It is hoped that liver biopsy, which is still required in order to assess prognosis appropriately, will be replaced in the future by less invasive methods based on combinations of biochemical markers of fibrosis and/or transient elastography, and that newer and less toxic orally administered drugs for HCV infection will become available.",
keywords = "Elderly, Hepatitis C, treatment, Peginterferon alfa 2b/ribavirin, therapeutic use, Peginterferon alfa, therapeutic use, Ribavirin, therapeutic use",
author = "Francesca Cainelli",
year = "2008",
language = "English",
volume = "25",
pages = "9--18",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Hepatitis C virus infection in the elderly

T2 - Epidemiology, natural history and management

AU - Cainelli, Francesca

PY - 2008

Y1 - 2008

N2 - Hepatitis C virus (HCV) infection frequently occurs in elderly individuals, with a prevalence in individuals aged >60 years of up to approximately 40%. Although progression to cirrhosis is accelerated and occurs more frequently in patients who acquire the infection in old age, this outcome is often not seen because most elderly infected patients acquired HCV when they were young. Data on progression of HCV infection to cirrhosis and eventually to hepatocellular carcinoma are often derived from studies of HCV-infected individuals who present or are referred to hospitals, and which are therefore likely to overestimate the seriousness of the disease; indeed, population-based studies indicate that in many elderly individuals the disease is asymptomatic and runs a fairly benign course. Treatment is based on use of pegylated interferon-α and ribavirin, and is overall less effective and more toxic in the elderly. Therefore, treatment should be carefully considered on an individual basis and proposed only in patients up to the age of 75 years with a significant risk of progression of liver disease, no serious co-morbidities and good life expectancy. All treated patients should be followed long term in order to assess the influence of therapy on the evolution of liver disease (decompensated cirrhosis, hepatocellular carcinoma) and survival. It is hoped that liver biopsy, which is still required in order to assess prognosis appropriately, will be replaced in the future by less invasive methods based on combinations of biochemical markers of fibrosis and/or transient elastography, and that newer and less toxic orally administered drugs for HCV infection will become available.

AB - Hepatitis C virus (HCV) infection frequently occurs in elderly individuals, with a prevalence in individuals aged >60 years of up to approximately 40%. Although progression to cirrhosis is accelerated and occurs more frequently in patients who acquire the infection in old age, this outcome is often not seen because most elderly infected patients acquired HCV when they were young. Data on progression of HCV infection to cirrhosis and eventually to hepatocellular carcinoma are often derived from studies of HCV-infected individuals who present or are referred to hospitals, and which are therefore likely to overestimate the seriousness of the disease; indeed, population-based studies indicate that in many elderly individuals the disease is asymptomatic and runs a fairly benign course. Treatment is based on use of pegylated interferon-α and ribavirin, and is overall less effective and more toxic in the elderly. Therefore, treatment should be carefully considered on an individual basis and proposed only in patients up to the age of 75 years with a significant risk of progression of liver disease, no serious co-morbidities and good life expectancy. All treated patients should be followed long term in order to assess the influence of therapy on the evolution of liver disease (decompensated cirrhosis, hepatocellular carcinoma) and survival. It is hoped that liver biopsy, which is still required in order to assess prognosis appropriately, will be replaced in the future by less invasive methods based on combinations of biochemical markers of fibrosis and/or transient elastography, and that newer and less toxic orally administered drugs for HCV infection will become available.

KW - Elderly

KW - Hepatitis C, treatment

KW - Peginterferon alfa 2b/ribavirin, therapeutic use

KW - Peginterferon alfa, therapeutic use

KW - Ribavirin, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=38049000829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049000829&partnerID=8YFLogxK

M3 - Review article

C2 - 18184025

AN - SCOPUS:38049000829

VL - 25

SP - 9

EP - 18

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 1

ER -